Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

Clinical trial NCT03244956 · COMPLETED

Trial details

NCT number

NCT03244956

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Status

COMPLETED

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2017-12-27

Primary completion

2022-05-23

Enrollment

40

View on ClinicalTrials.gov